A Study of the Safety and Effects of ADH-1 Given Intravenously as a Single Agent

Adherex Technologies

Status and phase: Completed; Phase 2

Conditions: Neoplasms

Treatments: Drug: ADH -1 (Exherin™)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00264433

Adherex Protocol # AHX-01-201

Details and patient eligibility

About

N-cadherin, a protein involved in blood vessel cell binding, is increased as cancer progresses, and is on the surface of many tumor cells. ADH-1 blocks N-cadherin. This study will test the safety and effects of ADH-1 in subjects with specific incurable, solid tumors with a protein biomarker called N-cadherin. This study will examine the clinical activity of ADH-1.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed written informed consent

• Male and female patients > or = 18 years of age with a solid tumor(s) refractory to standard curative therapy or for which no curative therapy exists

• Histologically proven advanced and/or metastatic solid tumor of one of the following histologies:

  • non-small cell lung cancer (squamous or non-squamous histology),
  • gastroesophageal carcinoma (squamous or adenocarcinoma histology),
  • renal cell carcinoma,
  • hepatocellular carcinoma,
  • adrenocortical carcinoma

• Measurable disease

• Immunohistochemical evidence of N-cadherin expression (at least 1+ positive) in archived or fresh tumor tissue

• Adequate performance status and organ function, as evidenced by hematological and biochemical blood testing and electrocardiogram (ECG)

Exclusion criteria

• Receipt of ADH-1 prior to this clinical study

• Chemotherapy, radiotherapy, or any other investigational drug within 30 days before study entry

• History of spinal cord compression, or history of primary brain tumor(s) or brain metastases (known or suspected) unless any lesions have completely resolved following appropriate treatment and there has been no recurrence for at least 6 months

• History of tumors that have shown clinically significant evidence of active bleeding (e.g., gross hemoptysis, hematemesis, hematuria, melena, or bleeding superficial tumor) within 12 weeks before study entry

• Stroke, major surgery, or other major tissue injury within 30 days before study entry

• History of:

  • uncontrolled congestive heart failure,
  • coronary artery disease, or life threatening arrhythmias;
  • myocardial infarction less than 12 months prior to study entry;
  • significant ECG abnormalities; or
  • known hypercoagulable states

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)